Xanomeline and Trospium Chloride Proven Successful Treatment For Schizophrenia

Our principal investigator, Dr. Sonnenberg, and colleagues have published their findings on successfully using a muscarinic M1 and M4 receptor agonist medication for treating symptoms of schizophrenia. 

Xanomeline and trospium chloride (formerly KarXT) is a newly approved treatment for schizophrenia that works differently from traditional antipsychotics by targeting muscarinic receptors rather than blocking dopamine. In a long-term study of stable patients transitioning from other medications, researchers explored patients’ personal experiences with this therapy through assessments conducted at six weeks of medication, and again at six months.

Most participants entered the study still experiencing significant symptoms such as hallucinations, low motivation, and difficulty concentrating. After starting xanomeline/trospium, over 60% of participants reported meaningful symptom improvement within the first six weeks, increasing to about 80% of participants by six months. Patients described these improvements as impactful, particularly in their ability to function in daily life.

Overall, the findings suggest that xanomeline/trospium may provide meaningful and sustained relief across multiple symptom areas, supporting improved functioning and recovery in people living with schizophrenia.

Click the link below to read the full article:

https://academic.oup.com/schizbullopen/article/7/1/sgag002/8464190